Alkem Laboratories Limited

rs,

74201 19th May, 2023 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 29,026 million

i today. Key highlights of Q4FY23 financial performance o • Total Revenue from Operations was ₹ 29,026 million, year-on-year growth of 16.9% India sales were ₹ 20,113 million, year-on-year growth of 17.0% Int

16.9%

cial performance o • Total Revenue from Operations was ₹ 29,026 million, year-on-year growth of 16.9% India sales were ₹ 20,113 million, year-on-year growth of 17.0% International sales were ₹ 8,570

₹ 20,113 million

Total Revenue from Operations was ₹ 29,026 million, year-on-year growth of 16.9% India sales were ₹ 20,113 million, year-on-year growth of 17.0% International sales were ₹ 8,570 million, year-on-year growth of 15.

17.0%

26 million, year-on-year growth of 16.9% India sales were ₹ 20,113 million, year-on-year growth of 17.0% International sales were ₹ 8,570 million, year-on-year growth of 15.6% • Earnings before Interest

₹ 8,570 million

of 16.9% India sales were ₹ 20,113 million, year-on-year growth of 17.0% International sales were ₹ 8,570 million, year-on-year growth of 15.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBIT

15.6%

ion, year-on-year growth of 17.0% International sales were ₹ 8,570 million, year-on-year growth of 15.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 3,533 million, o

₹ 3,533 million

n-year growth of 15.6% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 3,533 million, o resulting in EBITDA margin of 12.2% vs. 13.6% in Q4FY22. EBITDA grew by 4.8% YoY • R&D exp

12.2%

ax, Depreciation and Amortization (EBITDA) was ₹ 3,533 million, o resulting in EBITDA margin of 12.2% vs. 13.6% in Q4FY22. EBITDA grew by 4.8% YoY • R&D expenses for the quarter was ₹ 1,472 million,

13.6%

iation and Amortization (EBITDA) was ₹ 3,533 million, o resulting in EBITDA margin of 12.2% vs. 13.6% in Q4FY22. EBITDA grew by 4.8% YoY • R&D expenses for the quarter was ₹ 1,472 million, or 5.1% of

4.8%

was ₹ 3,533 million, o resulting in EBITDA margin of 12.2% vs. 13.6% in Q4FY22. EBITDA grew by 4.8% YoY • R&D expenses for the quarter was ₹ 1,472 million, or 5.1% of total revenue from operations

₹ 1,472 million

A margin of 12.2% vs. 13.6% in Q4FY22. EBITDA grew by 4.8% YoY • R&D expenses for the quarter was ₹ 1,472 million, or 5.1% of total revenue from operations compared to ₹ 1,635 million in Q4FY22 at 6.6% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6196737&linkS ecurityString=2020c81efc You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in